CD8A and neoplasm: Real time SERS in vivo imaging enables detection of dynamic longitudinal changes in CD8 and VEGFR2 in response to STING + TLR9 (stimulator of interferon genes + toll like receptor 9) immunotherapies, a treatment that increases tumor immunogenicity through a type I interferon response.